当前位置：
X-MOL 学术
›
Lancet Oncol.
›
论文详情
Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Correction to Lancet Oncol 2024; 25: 1310–24
The Lancet Oncology ( IF 41.6 ) Pub Date : 2024-10-11 , DOI: 10.1016/s1470-2045(24)00584-9
The Lancet Oncology ( IF 41.6 ) Pub Date : 2024-10-11 , DOI: 10.1016/s1470-2045(24)00584-9
Wang ES, Issa GC, Erba HP, et al. Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial. Lancet Oncol 2024; 25: 1310–24—In this Article, the colours in the key for ziftomenib 200 mg and ziftomenib 600 mg in figure 2B were switched. This correction has been made to the online version as of Oct 11, 2024.
更新日期：2024-10-11
京公网安备 11010802027423号